EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Whole‐Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma

Yi-Xian Liang, Yan-Ping Xie, Huan-Ming Yu, Wen-Juan Zhu, Cheng-Yi Yin, Zhao-Hui Dong, Xi-Lin Zhang iD

The Clinical Respiratory Journal · 2024

DOI: 10.1111/crj.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2024. Verfasst von Yi-Xian Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Exome Sequencing, Membrane Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, The Scientific Technology Projects of Health and Medicine of Zhejiang Province, Huzhou Science and Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lung adenocarcinoma (LUAD) is one of the major histopathological types of non‐small cell lung cancer (NSCLC), including solid, acinar, lepidic, papillary and micropapillary subtypes. Increasing evidence has shown that micropapillary LUAD is positively associated with a higher percentage of driver gene mutations, a higher incidence of metastasis and a poorer prognosis, while lepidic LUAD has a relatively better prognosis. However, the novel genetic change and its underlying mechanism in the progression of micropapillary LUAD have not been exactly determined.

Methods

A total of 181 patients with LUAD who underwent surgery at the First Affiliated Hospital of Huzhou University from January 2020 to December 2022 were enrolled. Three predominant lepidic and three predominant micropapillary LUAD tissue samples were carried out using whole‐exome sequencing. Comprehensive analysis of genomic variations and the difference between lepidic and micropapillary LUAD was performed. In addition, the TMEM229A Q200del mutation was verified using our cohort and TCGA‐LUAD datasets. The correlations between the TMEM229A Q200del mutation and the clinicopathological characteristics of patients with LUAD were further analyzed. The functions and mechanisms of TMEM229A Q200del on NSCLC cell proliferation and migration were also determined.

Results

The frequency of genomic changes in patients with micropapillary LUAD was higher than that in patients with lepidic LUAD. Mutations in EGFR , ATXN2 , C14orf180 , MUC12 , NOTCH1 , and PKD1L2 were concomitantly detected in three predominant micropapillary and three predominant lepidic LUAD cases. The TMEM229A Q200del mutation was only mutated in lepidic LUAD. Additionally, the TMEM229A Q200del mutation had occurred in 16 (8.8%) patients, and not found TMEM229A R76H and M346T mutations in our cohort, while TMEM229A mutations (R76H, M346T, and Q200del) occurred only in 1.0% of the TCGA‐LUAD cohort. Further correlation analysis between the TMEM229A Q200del mutation and clinicopathological characteristics suggested that a lower frequency of the Q200del mutation was significantly associated with positive lymph node metastasis, advanced TNM stage, positive cancer thrombus, and pathological features. Finally, overexpression of TMEM229A Q200del suppressed NSCLC cell proliferation and migration in vitro. Mechanistically, overexpression of TMEM229A and TMEM229A Q200del both reduced the expression level of phosphorylated (p)‐ERK and p‐AKT (Ser473), and the reduced protein level of p‐ERK in the TMEM229A Q200del group was more pronounced compared to the TMEM229A group.

Conclusion

Our results demonstrated that the TMEM229A Q200del mutant may play a protective role in the progression of LUAD via inactivating ERK pathway, providing a potential therapeutic target in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungExome SequencingMembrane ProteinsMutationHumansMaleFemaleMiddle AgedCell ProliferationPrognosisAgedCarcinoma, Non-Small-Cell LungCell Movement

Stichwörter der Autor:innen

lung adenocarcinomamicropapillary componentmutationtransmembrane protein 229Awhole‐exome sequencing

Substanzen

Membrane Proteins

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
  • Department of Respiratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
  • Department of Pathology, The First People's Hospital of Huzhou, Huzhou, Zhejiang, People's Republic of China.
  • Central Laboratory, Huzhou Key Laboratory of Translational Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.

ORCID-Profile: Xi-Lin Zhang

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • The Scientific Technology Projects of Health and Medicine of Zhejiang Province
  • Huzhou Science and Technology Fund

Zitieren

APA

Liang, Y. X., Xie, Y. P., Yu, H. M., Zhu, W. J., Yin, C. Y., Dong, Z. H., & Zhang, X. L. (2024). Whole‐Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70006

Vancouver

Liang YX, Xie YP, Yu HM, Zhu WJ, Yin CY, Dong ZH, et al. Whole‐Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma. The Clinical Respiratory Journal. 2024. doi:10.1111/crj.70006

BibTeX
@article{Liang2024,
  author = {Liang, Yi-Xian and Xie, Yan-Ping and Yu, Huan-Ming and Zhu, Wen-Juan and Yin, Cheng-Yi and Dong, Zhao-Hui and Zhang, Xi-Lin},
  title = {Whole‐Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma},
  journal = {The Clinical Respiratory Journal},
  year = {2024},
  doi = {10.1111/crj.70006}
}
Kostenlos starten →